SciFi Futures
← Concepts
Biotech & Medicine

Nexus-6 androids (replicants)

Bioengineered artificial humans, physically and mentally near-indistinguishable from people, manufactured as adults with implanted memories and a built-in four-year lifespan.

In shortNexus-6 androids (replicants), from Do Androids Dream of Electric Sheep? (Philip K. Dick, 1968), is at technology readiness level 2 of 9 (technology concept formulated) at its weakest link. Held back by Synthetic human genome design and assembly, Full-term ectogenesis and Mechanistic theory of neural computation. Science status: consistent with known physics; key effects unproven at scale. Estimated new funding to unlock: $31B–139B (a floor; some parts are priced only to early research).

Rosen Association Nexus-6 androids escape from Mars to Earth, detectable only by the Voigt-Kampff empathy test and bone-marrow analysis.
Do Androids Dream of Electric Sheep? by Philip K. Dick, 1968Set in 1992Overdue34 years past the story's date; weakest link still at TRL 2

Closest todaySynthetic genome projects, artificial-womb lamb trials and optogenetic false memories in mice.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • Designing a complete human-like organism with engineered traits
    • Assembly and delivery of megabase DNA into mammalian cells is inefficient
    • Cannot predict phenotype from designed sequence for complex traits like strength or intelligence
    • Testing designs requires embryos and developmental models
    TRL 2
    • Designing traits requires predicting phenotype from sequence
      ✕3 blockers›
      • Scores tag correlated variants rather than causal ones, so editing the top-ranked variant need not move the trait
      • Non-additive effects, pleiotropy and gene-environment interaction are unmodeled
      • Ancestry portability is poor because training cohorts are predominantly European
      TRL 3
    • Precise editing tools underpin incremental genome rewriting and testing
      ✕2 blockers›
      • Delivery to tissues beyond liver
      • Long-term off-target safety
      TRL 6
  • criticalFull-term ectogenesisbottleneck
    Growing bodies outside a mother, and rapidly to adulthood
    • The gap between day-14 embryo culture and artificial-placenta viability covers organogenesis, the hardest and least substitutable phase
    • No artificial implantation or placental organ exists to supply hormones and nutrient exchange during that gap
    • Scaling implies thousands of parallel units with sterility and uninterrupted power for nine months each
    TRL 2
    • The early half cannot be built without reconstructing implantation and placental exchange
      ✕3 blockers›
      • The placenta's endocrine and nutrient-exchange functions have not been reproduced by any device or culture
      • Maternal immune tolerance at the interface is not understood well enough to substitute for
      • Human implantation cannot be studied past the 14-day limit, so the critical window is inaccessible
      TRL 3
    • An engineered placenta is a vascularized tissue that must be grown, not just machined
      ✕4 blockers›
      • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
      • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
      • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
      • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
      TRL 4
      • Without a capillary network, tissue thicker than a few hundred microns dies
        ✕3 blockers›
        • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
        • Engineered endothelium is thrombogenic, so perfused constructs clot
        • No method guides anastomosis of a construct's vasculature to host vessels at scale
        TRL 3
      • Banked-cell organs are not patient-matched, so acceptance must be engineered
        ✕3 blockers›
        • Chronic antibody-mediated rejection proceeds even under current immunosuppression
        • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
        • No assay predicts which recipients can be safely weaned off drugs
        TRL 5
      • One organ needs 10^10-10^11 clinical-grade cells of several types
        ✕3 blockers›
        • Genomic instability and drift accumulate over the expansion needed for 10^11 cells
        • Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
        • Cost per cell at current media and reagent prices makes a printed organ unaffordable
        TRL 6
    • Supplies the late-gestation half of the problem
      ✕4 blockers›
      • Miniaturization - the lamb model weighs 1-3 kg while a 23-week human fetus is about 500 g, with shorter umbilical cannulation distances
      • Umbilical vessel vasospasm and thrombosis during cannulation and over weeks of support
      • Infection control in a continuously exchanged sterile fluid environment
      • No agreed proof-of-concept endpoint or animal model that maps onto human neonatal outcomes
      TRL 5
      • Sterile fluid exchange, nutrition and waste handling must run continuously without interruption
        ✕2 blockers›
        • Food production closure
        • Microbial and ecological stability over years
        TRL 5
      • Gas exchange through the umbilical circuit for weeks is the core function
        ✕3 blockers›
        • Blood-surface contact activates coagulation, so runs depend on anticoagulation that causes bleeding in fragile patients
        • Oxygenator plasma leakage and fiber fouling limit single-circuit life
        • Hemolysis and platelet consumption scale with pump shear and circuit length
        TRL 7
  • Designing brains with human-level cognition and tuned empathy
    • Unknown sufficient level of biological detail
    plausibleTRL 2
    • Wiring diagrams constrain and test circuit models
      ✕3 blockers›
      • Human proofreading of AI segmentation dominates cost; 2025 methods imply tens of billions of dollars for one mouse brain
      • Imaging throughput and storage; a human brain at EM resolution is of order 100+ exabytes of raw data
      • Sectioning or expanding whole large brains without tissue loss or distortion
      TRL 3
      • Ultrastructure must survive preservation before it can be imaged
        ✕3 blockers›
        • Ischemic damage starts within minutes of circulatory arrest, before perfusion can begin
        • Aldehyde fixation may destroy molecular state (phosphorylation, receptor conformation) that could carry memory
        • No assay proves preserved tissue still contains the information an emulation would need
        TRL 4
      • Automated segmentation and tracing of exabyte-scale image volumes
        ✕2 blockers›
        • Grid power and interconnection queues
        • Advanced-node chip and HBM memory supply
        TRL 8
  • Rachael's implanted childhood memories
    ✕4 blockers›
    • Human engrams cannot be labeled; the mouse toolkit depends on transgenic c-fos tagging
    • Memory is distributed across an engram complex in many regions, not one addressable site
    • Writing content requires knowing the ensemble code for arbitrary experience, which is unknown
    • Specificity; stimulation that strengthens one memory also perturbs neighbours
    plausibleTRL 3
    • Writing a memory requires knowing what code represents its content
      plausibleTRL 2
    • Activity-dependent labeling in humans would need brain-wide gene delivery
      ✕3 blockers›
      • Receptor targeting is species-specific; capsids binding human TfR1 often fail in macaque
      • Pre-existing anti-AAV immunity excludes a large fraction of patients and blocks redosing
      • Dose needed for brain-wide coverage drives liver toxicity and manufacturing cost
      TRL 4
      • Designed capsid and shuttle proteins are the main route to receptor-specific transcytosis
        ✕1 blocker›
        • Designing catalysis and conformational dynamics
        TRL 6
    • Engram ensembles must be addressed at single-cell scale in deep structures
      ✕2 blockers›
      • Tissue response degrades signal over years
      • Channel count and wireless bandwidth
      TRL 6
      • Channel count is limited by wireless data and power budget
        ✕3 blockers›
        • Tissue heating caps implant power at a few hundred milliwatts, which bounds radio and compute
        • Raw broadband neural data exceeds the link, forcing on-implant spike detection and compression
        • Battery or wireless-power lifetime versus the decades a permanent interface implies
        TRL 5
        • Implant power density sets what telemetry and on-board compute are affordable
          ✕2 blockers›
          • Cycle life of lithium-metal anodes
          • Thermal runaway safety
          TRL 6
  • Engineering limited lifespan and enhanced strength into the germline
    ✕3 blockers›
    • Mosaicism - edits arrive after the first division, so cells of the same embryo differ
    • On-target large deletions, chromosome loss and chromothripsis occur in edited embryos and are invisible to biopsy-based testing
    • A biopsy of a few cells cannot certify the genome of the whole future person, so safety cannot be established before a birth
    TRL 3
    • Editing and screening gametes before fertilization avoids embryo mosaicism altogether
      ✕3 blockers›
      • Human oocyte maturation needs months of follicle growth that culture cannot yet sustain
      • Meiotic recombination and chromosome segregation are error-prone outside the ovary, giving aneuploidy
      • Imprinting marks are set during germ-cell development and are mis-set in vitro, with no safety assay short of a live birth
      TRL 3
    • Any multi-trait germline change needs many simultaneous precise edits
      ✕3 blockers›
      • Structural variants and large deletions accumulate with edit count and are missed by short-read screening
      • Edited cell lines lose clonogenic and developmental potency after many rounds of editing
      • No method reaches the thousands of edits implied by whole-genome rewriting
      TRL 6

Who could unlock it

Synthetic human genome design and assemblyTRL 2bottleneck
  • Jason ChinResearcher, MRC Laboratory of Molecular Biology and the Generative Biology Institute, Ellison Institute of Technology, Oxford
    Leads SynHG and previously built synthetic recoded E. coli genomes; his group is developing the assembly tools for megabase-scale human sequence
  • SynHG (Synthetic Human Genome Project)Program
    Five-year project launched June 2025 with GBP 10M from Wellcome across Cambridge, Kent, Manchester, Oxford and Imperial, targeting a first synthetic human chromosome (about 2 percent of the genome)
  • Patrick Yizhi CaiResearcher, University of Manchester
    Designed synthetic yeast chromosomes for Sc2.0 and is a SynHG co-investigator, bringing the only completed whole-eukaryotic-genome synthesis experience to the human effort
  • Ansa BiotechnologiesStartup
    Enzymatic DNA synthesis using TdT-nucleotide conjugates; now delivers 50 kb clonal DNA in 24 days at $0.28-0.38 per base pair after a $54.4M Series B in October 2025 ($134M total)
Full-term ectogenesisTRL 2bottleneck
  • Jacob HannaResearcher, Weizmann Institute of Science
    Grew natural mouse embryos ex utero from E5.5 to E11 through organogenesis (Nature, 2021) and generated transgene-free post-gastrulation whole embryo models from naive stem cells (Cell Stem Cell, 2025); holds an ERC grant titled ExUteroEmbryogenesis
  • Alejandro Aguilera-CastrejonResearcher, Janelia Research Campus, HHMI
    Built the roller and perfusion ex utero culture platform in the Hanna lab and now works explicitly toward birthing a mouse from an incubator
  • Renewal BioStartup
    Israeli company co-founded by Hanna in 2022 that licensed the Weizmann ex utero and synthetic-embryo patents (about $9M raised via NFX) to grow early tissue as a cell source
  • Vitara BiomedicalStartup
    Working the opposite end of the same problem - fluid-filled support from roughly 22 weeks of human gestation onward, the only part of full-term ectogenesis anywhere near clinical use
Mechanistic theory of neural computationTRL 2bottleneck
  • Philip ShiuResearcher, Eon Systems
    Built the leaky integrate-and-fire whole fly brain model that predicts sensorimotor circuit responses (Nature 2024)
  • Srinivas TuragaResearcher, HHMI Janelia Research Campus
    Co-led connectome-constrained networks that predict neural activity across the fly visual system (Nature 2024)
  • Larry AbbottResearcher, Columbia University
    Theoretical neuroscientist; co-director of the Zuckerman Institute's Center for Theoretical Neuroscience
  • Allen InstituteAcademic lab
    MICrONS functional connectomics and a 230,000-cell biophysical model of mouse visual cortex
Engram-level memory read and writeTRL 3
  • Susumu TonegawaResearcher, MIT Picower Institute
    His lab first optogenetically reactivated and implanted false memories in tagged engram cells in mice (2012-2013)
  • Sheena JosselynResearcher, SickKids and University of Toronto
    Showed engram allocation, erasure and artificial memory formation in mice; 2025 Cell paper on stress-inflated engrams
  • Steve RamirezResearcher, Boston University
    Engram manipulation to alleviate maladaptive memory states in mice
  • Robert HampsonResearcher, Wake Forest University School of Medicine
    Hippocampal memory-decoding-model stimulation facilitated content-specific recall in epilepsy patients (Front. Comput. Neurosci. 2024)

Beyond engineering

  • Creating sentient beings as property is slavery under any human-rights framework
  • Human reproductive cloning and germline engineering bans